Filing Details
- Accession Number:
- 0001628280-24-004125
- Form Type:
- 13G Filing
- Publication Date:
- 2024-02-08 19:00:00
- Filed By:
- Cumberland Pharmaceuticals Inc
- Company:
- Cumberland Pharmaceuticals Inc (NASDAQ:CPIX)
- Filing Date:
- 2024-02-09
- SEC Url:
- 13G Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| A.J. Kazimi | 5,721,267 | 5,721,267 | 5,721,267 | 40.14% |
Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________________
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 11)*
__________________________________________
Cumberland Pharmaceuticals Inc.
_______________________________________
(Name of Issuer)
Common Stock
__________________________________________
(Title of Class of Securities)
230770109
__________________________________________
(CUSIP Number)
December 31, 2023
__________________________________________
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
o Rule 13d-1(c)
x Rule 13d-1(d)
| * | The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. | ||||
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 230770109 | ||||||||
| 1 | NAMES OF REPORTING PERSONS. A.J. Kazimi | |||||||||||||||||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) Not applicable (a) o (b) o | |||||||||||||||||||
| 3 | SEC USE ONLY | |||||||||||||||||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION United States | |||||||||||||||||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | 5 | SOLE VOTING POWER 5,721,267 | ||||||||||||||||||
| 6 | SHARED VOTING POWER None | |||||||||||||||||||
| 7 | SOLE DISPOSITIVE POWER 5,721,267 | |||||||||||||||||||
| 8 | SHARED DISPOSITIVE POWER None | |||||||||||||||||||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,721,267 | |||||||||||||||||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable o | |||||||||||||||||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 40.14% | |||||||||||||||||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN | |||||||||||||||||||
Page 2 of 5 pages
Item 1.
| (a) | Name of Issuer | |||||||
| Cumberland Pharmaceuticals Inc. | ||||||||
| (b) | Address of Issuer's Principal Executive Offices | |||||||
| 1600 West End Avenue, Suite 1300, Nashville, TN 37203 | ||||||||
Item 2.
| (a) | Name of Person Filing | |||||||
| A.J. Kazimi | ||||||||
| (b) | Address of Principal Business Office or, if none, Residence | |||||||
| 1600 West End Avenue, Suite 1300, Nashville, TN 37203 | ||||||||
| (c) | Citizenship | |||||||
| United States | ||||||||
| (d) | Title of Class of Securities | |||||||
| Common Stock | ||||||||
| (e) | CUSIP Number | |||||||
| 230770109 | ||||||||
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
Not applicable
Item 4. Ownership.
| (a) | Amount beneficially owned: | |||||||
| 5,721,267 | ||||||||
| (b) | Percent of class: | |||||||
| 40.14% | ||||||||
Page 3 of 5 pages
| (c) | Number of shares as to which the person has: | |||||||
| (i) | Sole power to vote or to direct the vote | |||||||
| 5,721,267 | ||||||||
| (ii) | Shared power to vote or to direct the vote | |||||||
| None. | ||||||||
| (iii) | Sole power to dispose or to direct the disposition of | |||||||
| 5,721,267 | ||||||||
| (iv) | Shared power to dispose or to direct the disposition of | |||||||
| None. | ||||||||
Item 5. Ownership of Five Percent or Less of a Class
Not applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
Not applicable
Item 8. Identification and Classification of Members of the Group
Not applicable
Item 9. Notice of Dissolution of Group
Not applicable
Item 10. Certification
Not applicable
Page 4 of 5 pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| February 9, 2024 | |||||
| Date | |||||
| /s/ A.J. Kazimi* | |||||
| Signature | |||||
| A.J. Kazimi, Chief Executive Officer | |||||
| Name/Title | |||||
* By: /s/ John Hamm, as attorney-in-fact, pursuant to a Power of Attorney dated June 10, 2021 and filed with the SEC on June 11, 2021.
Page 5 of 5 pages